{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04448106",
            "orgStudyIdInfo": {
                "id": "CTX0020-002"
            },
            "organization": {
                "fullName": "Celltex Therapeutics Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis",
            "officialTitle": "Clinical Study for Subjects With Osteoarthritis of Knees, Hips, and Shoulders Using a Combination of Intravenous Infusions With Intra-articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)",
            "acronym": "AdMSCs",
            "therapeuticArea": [
                "Orthopedics"
            ],
            "study": "autologous-adipose-tissue-derived-mesenchymal-stem-cells-admscs-for-osteoarthritis"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-04",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-25",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-06-22",
            "studyFirstSubmitQcDate": "2020-06-23",
            "studyFirstPostDateStruct": {
                "date": "2020-06-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-04-13",
            "lastUpdatePostDateStruct": {
                "date": "2023-04-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celltex Therapeutics Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase 2 open-label, 6 arms (1 study group and 1 control group for each joint category), randomized control group clinical study with 300 subjects diagnosed with osteoarthritis of knees (n=100), hips (n=100) and shoulders (n=100). The study subjects will be evaluated for disease-associated severity according to symptoms, such as pain, mobility, daily active life, and functions using arthritis society established specific measurement tools related to the joints (KOOS and KSS for OA-knees: HOOS and HHS for OA-hips and ASES and CSS for OA-shoulders)."
        },
        "conditionsModule": {
            "conditions": [
                "Osteoarthritis, Knee",
                "Osteoarthritis, Hip",
                "Osteoarthritis Shoulder"
            ],
            "keywords": [
                "Autologous Adipose-derived Stem Cells (AdMSCs)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "The Phase 2 study is an open-label, 6 arms, randomized, control group clinical study conducted in multiple clinical facilities.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Patients and evaluators",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 300,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Phase 2 Arm 1 - OA Knee",
                    "type": "EXPERIMENTAL",
                    "description": "50 subjects receive two doses of 2.0-2.86 x 10\\^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10\\^6 cells/kg via intra-articular injection into the injured joint.",
                    "interventionNames": [
                        "Biological: Celltex- AdMSCs"
                    ]
                },
                {
                    "label": "Phase 2 Arm 2 OA Knee",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Control group- 50 subjects receive three doses of 2.0-2.86 x 10\\^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                    "interventionNames": [
                        "Biological: Celltex- AdMSCs"
                    ]
                },
                {
                    "label": "Phase 2 Arm 3 - OA Hip",
                    "type": "EXPERIMENTAL",
                    "description": "50 subjects receive two doses of 2.0-2.86 x 10\\^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10\\^6 cells/kg via intra-articular injection into the injured joint.",
                    "interventionNames": [
                        "Biological: Celltex- AdMSCs"
                    ]
                },
                {
                    "label": "Phase 2 Arm 4 - OA Hip",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Control group- 50 subjects receive three doses of 2.0-2.86 x 10\\^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                    "interventionNames": [
                        "Biological: Celltex- AdMSCs"
                    ]
                },
                {
                    "label": "Phase 2 Arm 5 - OA Shoulder",
                    "type": "EXPERIMENTAL",
                    "description": "50 subjects receive two doses of 2.0-2.86 x 10\\^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10\\^6 cells/kg via intra-articular injection into the injured joint.",
                    "interventionNames": [
                        "Biological: Celltex- AdMSCs"
                    ]
                },
                {
                    "label": "Phase 2 Arm 6 - OA Shoulder",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Control group- 50 subjects receive three doses of 2.0-2.86 x 10\\^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                    "interventionNames": [
                        "Biological: Celltex- AdMSCs"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Celltex- AdMSCs",
                    "description": "Autologous adipose-derived stem cells Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue",
                    "armGroupLabels": [
                        "Phase 2 Arm 1 - OA Knee",
                        "Phase 2 Arm 2 OA Knee",
                        "Phase 2 Arm 3 - OA Hip",
                        "Phase 2 Arm 4 - OA Hip",
                        "Phase 2 Arm 5 - OA Shoulder",
                        "Phase 2 Arm 6 - OA Shoulder"
                    ],
                    "otherNames": [
                        "AdMSCs"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.",
                    "description": "safety",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Any organ damage or safety concerns determined by SMAC 20 blood test.",
                    "description": "Safety",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients",
                    "description": "efficacy",
                    "timeFrame": "12 month"
                },
                {
                    "measure": "Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "changes in joint images (X-ray or MRI) from the baseline",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Number of patients achieve visual analog scale (VAS) pain improvement above 30%, 50% and 70% from the baseline",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Number of patient achieve Image (X-ray or MRI) improvement above 30%, 50% and 70% from the baseline",
                    "description": "efficacy",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age above 18 years\n* Male or female\n* Subjects in study group must have banked AdMSCs at Celltex (already passed communicable disease screen tests for HIV, syphilis and Hepatitis B and C during banking stage)\n* Must understand and voluntarily sign an Informed Consent for study participation obtained prior to undergoing any study-specific procedures\n* Must be diagnosed as OA-knees, OA-hips, or OA-shoulders by radiographic criteria and physical examination.\n\nExclusion Criteria:\n\n* Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start\n* Unwillingness or inability to comply with study procedures\n* Patients with serious basic diseases that affect survival, including blood diseases, cachexia, active bleeding, severe malnutrition, etc.\n* Clinically active malignant disease\n* Previous thrombotic disorder\n* History of known pulmonary embolism or known secondary anti-phospholipid syndrome\n* Known or suspected hypersensitivity to any components used to culture the AdMSCs, e.g. BSA and sulfur-containing products (e.g., DMSO)\n* Major trauma or surgery within 14 days of study treatment start\n* Mental condition rendering the subject (or the subject's legally acceptable representative\\[s\\]) unable to understand the nature, scope and possible consequences of the study\n* Alcohol, drug, or medication abuse within one year prior to study treatment start\n* Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study\n* Irreversible severe end-organ failure, such as heart failure/attack, stroke, liver and renal failure due to other disease conditions\n* Patients or family history with a hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.\n* History of long-term use of immunosuppressive agents\n* Organ transplants in the previous 6 months\n* Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jane Young",
                    "role": "CONTACT",
                    "phone": "7135901000",
                    "email": "jyoung@celltexbank.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Derek W Guillory, MD.",
                    "affiliation": "Root Causes Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanley C Jones",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77098",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sally McGahee, BS",
                            "role": "CONTACT",
                            "phone": "713-590-1000",
                            "phoneExt": "147",
                            "email": "smcgahee@celltexbank.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010003",
                    "term": "Osteoarthritis"
                },
                {
                    "id": "D000020370",
                    "term": "Osteoarthritis, Knee"
                },
                {
                    "id": "D000015207",
                    "term": "Osteoarthritis, Hip"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001168",
                    "term": "Arthritis"
                },
                {
                    "id": "D000007592",
                    "term": "Joint Diseases"
                },
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000012216",
                    "term": "Rheumatic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12926",
                    "name": "Osteoarthritis",
                    "asFound": "Osteoarthritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22168",
                    "name": "Osteoarthritis, Knee",
                    "asFound": "Osteoarthritis, Knee",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17912",
                    "name": "Osteoarthritis, Hip",
                    "asFound": "Osteoarthritis, Hip",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4476",
                    "name": "Arthritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M10621",
                    "name": "Joint Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15045",
                    "name": "Rheumatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6323",
                    "name": "Collagen Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                }
            ]
        }
    },
    "hasResults": false
}